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The weight of evidence from numerous clinical studies 
supports the use of IVIG, particularly at higher doses, in 
the treatment of a wide range of autoimmune disorders. 
Extensive experience has documented the safety of IVIG 
therapy but its present relatively high cost necessitates 
firmly establishing its efficacy. There is an acute need to 
define those disease states where IVIG is indicated and 
effective. Large-scale, possibly multicentered, clinical 
trials employing rigorous controls will resolve these ques- 
tions. Concurrent fundamental immunologic studies will 
elucidate the mechanisms underlying the clinical effects. 
We are experiencing an exciting new era of effective 
immunotherapies and intravenous gamma-globulin prep- 
arations have already secured an important place in the 
therapeutic armamentarium. While one must guard 
against unsubstantiated applications, critical exploration 
of new uses for this unique product is warranted. 
KEY WORDS: Intravenous immunoglobulin; autoimmunity; im- 
munomodulation. 
INTRODUCTION 
Antiinflammatory and immunosuppressive drugs 
have been the primary agents for the treatment of 
autoimmune disorders. While our understanding of 
the scope and pathogenic mechanisms of autoim- 
mune diseases has expanded greatly, newer forms 
of therapy have also been proposed and developed. 
Included among these are plasmapheresis, antiidio- 
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typic antibodies, and biological response modifier 
substances. 
Gamma-globulin replacement is the definitive 
treatment for humoral immunodeficiency disorders. 
With the advent of intravenous immunoglobulin 
(IVIG) preparations, therapeutic application was 
extended to, among other indications, the treatment 
of idiopathic thrombocytopenia purpura (ITP). Be- 
cause of the role of antiplatelet antibodies in the 
pathogenesis of ITP, it can be considered to have an 
underlying autoimmune etiology. The mecha- 
nism(s) of action of IVIG in the treatment of ITP 
remains poorly understood. However, two hypoth- 
eses have gained popularity: (i) Fc receptor block- 
ade and (ii) antiidiotypic antibodies directed against 
the autoantibodies. Based upon earlier use of IVIG 
in the treatment of ITP associated with antiplatelet 
autoantibodies, this therapy has been extended to 
the wide variety of other autoimmune disorders. 
Gupta (1) has previously described many of these 
applications; the present review updates and ex- 
tends his earlier report. As used herein the defini- 
tion of autoimmune disease is very broad and 
encompasses a host of conditions where the under- 
lying immunopathogenic mechanisms include the 
presence of autoantibodie s. 
SPECIFIC DISEASES 
81 
Idiopathic Thrombocytopenia Purpura 
Although the original and primary indication for 
IVIG replacement therapy remains antibody deft- 
0271-9142/90/0300-0081506.00/0 © 1990 Plenum Publishing Corporation 
82 SCHWARTZ 
ciency states, its use in the treatment of both acute 
and chronic ITP has also been approved. Irnbach 
and colleagues (2) were the first to report on the 
efficacy of treatment of ITP of childhood with 
high-dose IVIG. The initial rationale for this form of 
therapy was the observation that two congenitally 
agammaglobulinemic patients with severe thromb- 
ocytopenia manifested significant increases in plate- 
let counts after administration of IVIG. IVIG was 
also found to be effective in treating thrombocy- 
topenia associated with the Wiskott-Aldrich syn- 
drome (3), a disorder in which the presence of 
platelet-associated antibodies has been described 
(4). From these earlier studies numerous others 
have emerged (see Ref. 5 for a review). As the 
subject of IVIG for the treatment of ITP has been 
extensively reviewed previously, only a limited 
discussion is presented here. Lusher and Warrier 
(6) specifically distinguished between the use of 
IVIG to treat acute, postinfectious ITP of childhood 
and its use to treat chronic, autoimmune ITP, which 
generally affects adults. While the former is often a 
benign, self-limited disease with a high probability 
of spontaneous remission, the latter tends to be 
resistant to corticosteroids and may thus be more 
amenable to IVIG therapy, possibly in preparation 
of splenectomy. 
Management of acquired, immune thrombocy- 
tompenias with IVIG has also been described by 
several investigators. It has been shown that throm- 
bocytopenia due to alloimmunization after platelet 
transfusions can be ameliorated by high-dose IVIG 
therapy (7-11), as can posttransfusion purpura (12, 
13), neonatal immune thrombocytopenia (14-16), 
and autoimmune thrombocytopenia of pregnancy 
(17, 18). Although the latter syndromes are not 
classical autoimmune disorders as they reflect de 
novo sensitization, nevertheless, their underlying 
pathogenic mechanisms are very similar to autoim- 
mune phenomena. 
Hemophilia Associated with Antihemophilic 
Factor Inhibitors 
While classic hemophilia is an X-linked disorder 
of blood coagulation due to a nonfunctional variant 
of antihemophilic factor (factor VIII), acquired in- 
hibitors of antihemophilic factor have been de- 
scribed which cause a coagulopathy clinically sim- 
ilar to hemophilia. These inhibitors have been 
identified as antibodies. A 39-year-old patient with 
hemophilia B was found to have circulating antibod- 
ies capable of functionally inhibiting factor IX (19). 
These antibodies were probably of the IgG class, as 
they could be removed by protein A-Sepharose 
chromatography. However, when extracorporeal 
treatment by protein A-Sepharose adsorption was 
attempted, the patient subsequently developed a 15 
fold increase in antibody titer. When immunoad- 
sorption was followed by IVIG, no such rebound 
phenomenon was observed, and it was followed up 
by a prolonged suppression of anti-factor IX anti- 
body production. 
Replacement therapy with purified factor VIII for 
the treatment of hemophilia is sometimes compli- 
cated by the development of inhibitory antibodies 
against factor VIII. Two such patients treated with 
high-dose IVIG, however, showed a significant rise 
in inhibitor titers after treatment (20). In contrast, 
two other reports described the successful treat- 
ment of patients with hemophilia A and serum 
factor VIII inhibitors (21,22). Clinical improvement 
was paralleled by the disappearance of inhibitory 
anti-factor VIII antibodies and resulted in pro- 
longed remission lasting at least 7 months. Follow- 
up was unavailable. At present it is not possible to 
predict which patients with hemophilia and antihe- 
mophilic factor antibodies will respond to IVIG. 
Although empirical therapy can resolve the ques- 
tion, it must be pointed out that such treatment has 
been complicated by a significant rise in inhibitor 
titers, thus making factor VIII replacement even 
more difficult. 
Sultan and colleagues demonstrated that treat- 
ment of hemophilia due to autoantibodies against 
antihemophilic factor (factor VIIIc) with IVIG 
was associated with the presence of antiidiotypic 
antibodies against the pathologic autoantibodies 
within the immunoglobulin preparation (23). This 
was based on the observation that the in vivo 
clinical response was correlated with the ability of 
an F(ab')2 fraction of the immunoglobulin prepa- 
ration to reverse the inhibition of factor VIII 
activity by autoantibodies from hemophiliac pa- 
tients in vitro. 
Autoimmune Hemolytic Anemia 
Immunosuppressive drugs with or without plas- 
mapheresis or splenectomy have been the principal 
treatment modalities for severe autoimmune hemo- 
lytic anemias. Earlier reports suggested that IVIG 
therapy was ineffective in treating autoimmune he- 
molytic anemia particularly of the "warm" (IgG- 
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mediated) type (24, 25). However, IVIG has been 
used to successfully treat a case of Evans syn- 
drome, refractory autoimmune hemolytic anemia 
with ITP (26). The rationale for the use of IVIG in 
this setting was its previously demonstrated efficacy 
in ITP and presumed similar immunopathogenesis 
of hemolysis and thrombocytopenia. In this case of 
a 5-month-old boy, who tailed to respond to high- 
dose pulse therapy with corticosteroids and subse- 
quent cyclophosphamide administration, remission 
was achieved rapidly after two courses of 1.6 g of 
IVIG/kg given over 4 days. Although the patient 
was also on chronic prednisone, it was gradually 
withdrawn and discontinued after IVIG treatment 
without relapse. Similarly a 75-year-old man with 
idiopathic warm autoimmune hemolytic anemia 
who had been unsuccessfully treated with predni- 
sone, azathioprine, and splenectomy showed imme- 
diate but transient improvement after two courses 
of high-dose IVIG (27). A third course of treatment 
resulted in a prolonged remission. WIG has been 
deemed particularly useful when autoimmune he- 
molytic anemia is associated with immunodefi- 
ciency syndromes (28). Several other reports sub- 
stantiate the use of IVIG in autoimmune hemolytic 
anemias due to hemolytic antibodies of the IgG 
class (29-3 I). 
Although pure red-cell aplasias are distinctly dif- 
ferent from hemolytic anemias in that erythroid 
precursor cells of the bone marrow are usually 
absent in the former, many cases of pure red-cell 
aptasia may be due to immune suppression of 
erythropoiesis by IgG autoantibodies. McGuire et 
aL described the successful treatment of a 4- 
year-old girl with antibody-mediated, pure red-cell 
aplasia (32). Since both F(ab') z fragments and intact 
IgG molecules from pooled donor gamma-globulin 
could reverse the cytotoxic activity of the patient's 
IgG fraction on hematopoietic progenitor cells in 
vitro, they concluded that the therapeutic effect 
may be due to antiidiotypic antibodies recognizing 
the patient's IgG autoantibodies. 
One patient, a 60-year-old man, with a presumed 
autoimmune pure white-cell aplasia has also been 
treated with high-dose IVIG (33). Although a rapid 
remission was achieved, it was short-lived, requir- 
ing other therapeutic intervention. 
A u t o i m m u n e  Neutropenia  
Only a few studies have demonstrated the ef- 
ficacy of WIG in the treatment of autoimmune 
neutropenia. An early report by Pollock et al (34) 
showed a transient response of autoimmune neutro- 
penia to high-dose IVIG. It was subsequently dem- 
onstrated that IVIG produced a more protracted 
improvement in two symptomatic children with 
autoimmune neutropenia of infancy (35). The in- 
creased neutrophil count was associated with nor- 
mal functions and evidence was presented suggest- 
ing that IVIG may work through Fc receptor 
blockade and/or decreased antineutrophil antibody 
synthesis. Similar positive effects of IVIG on au- 
toimmune neutropenia were also observed in other 
studies (36-38). 
Felty's syndrome is an autoimmune disease con- 
sisting of neutropenia, splenomegaly, and rheuma- 
toid arthritis. The neutropenia appears to be sec- 
ondary to production of antineutrophil antibodies. 
Several patients with Felty's syndrome have been 
treated with IVIG but failed to respond to therapy 
(39, 40). As this observation conflicts with reports 
of the successful treatment of other immune cytope- 
nias with IVIG, it has been suggested that the 
neutropenia of Felty's syndrome may involve dif- 
ferent pathologic mechanisms (40). 
Murakami et al. (41) reported an interesting dis- 
sociation between the response of autoimmune neu- 
tropenia and thrombocytopenia in a 15-year-old 
girl. The neutropenia initially responded to IVIG 
but the thrombocytopenia did not. On subsequent 
treatment both neutrophil and platelet counts in- 
creased significantly. Again, it was suggested that 
different immunopathogenic mechanisms may be 
involved in various autoimmune cytopenias. 
In another case of combined autoimmune throm- 
bocytopenia and neutropenia, Ricevuti et aL exam- 
ined the effect of exogenous IVIG on a variety of 
neutrophit functions (42). Most significantly was the 
coincident improvement of depressed neutrophil 
chemotaxis after treatment. This was paralleled by 
a disappearance in antineutrophil autoantibodies 
over a 6-day period. Within 30 days, antineutrophil 
antibodies reappeared and neutrophil numbers and 
chemotaxis were again depressed. It was also inter- 
esting to note that the serum of the untreated 
patient could suppress the mobility of normal donor 
neutrophils, but after IVIG treatment the patient's 
serum was no longer inhibitory. After 30 days, the 
patient's serum was again suppressive of chemo- 
taxis coincident with the return of neutropenia and 
antineutrophil antibodies. 
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Myasthenia Gravis 
Myasthenia gravis (MG) is an autoimmune disor- 
der wherein autoantibodies to the acetylcholine 
receptor at the myoneural junction block normal 
transmission of impulses from the nerve terminus to 
the muscle fiber. Clinical manifestations of MG 
include motor weakness and easy fatigability. Ther- 
apy of MG includes the use of anticholinesterases to 
potentiate and prolong the signal at the motor end 
plate as well as immunosuppressive therapy includ- 
ing corticosteroids and azathioprine. Early prelim- 
inary reports suggested that high-dose IVIG could 
result in neurologic improvement and dimunition of 
acetylcholine receptor antibodies (43, 44). While 
improvement has been further reported in MG (44, 
46), no change in acetylcholine receptor antibodies 
was noted in another study (47). In a more exten- 
sive series and report, Arsura et al. described 
similar beneficial effects of high-dose IVIG to treat 
and produce sustained improvement in 11 patients 
with MG (48). It was interesting to note that the 
response to IVIG therapy was independent of a 
variety of parameters including previous therapy, 
coexisting thymoma, or a history of thymectomy. 
In contrast to some previous reports, no depression 
of elevated acetylcholine receptor antibody titers 
was observed despite clinical improvement. 
Cook and her colleagues have described some 
interesting changes in immunologic parameters oc- 
curring during the course of IVIG treatment of MG 
(49). While a slight decrease in the total number of 
circulating lymphocytes was observed, CD16 + and 
CD8 + mononuclear leukocytes showed a significant 
increase proportionate to the serum level of IgG 
achieved. The authors speculated that these might 
represent natural killer cells. Other findings in- 
cluded an increase in IgG-specific, Fc receptor- 
bearing cells which could potentially be suppressor 
T lymphocytes and decreases in the absolute num- 
ber of helper T cells. The latter observations may 
partially elucidate the immunoregulatory mecha- 
nisms underlying the efficacy of high-dose IVIG for 
the treatment of MG. 
Seizure Disorders 
The inclusion of seizure disorders within the 
category of autoimmune diseases is admittedly ar- 
bitrary. However, evidence does exist for the role 
of immunologic mechanisms in the pathogenesis of 
some forms of epilepsy (50). Several investigators 
have utilized IVIG for the treatment of intractable 
childhood epilepsies, with a wide range of results 
(51-56). Although perceived clinical improvement 
could occasionally be correlated with objective neu- 
rologic evidence, all of these reports lacked rigor- 
ous controls. 
Regarding hypothetical mechanisms of action of 
IVIG in the treatment of seizures, it is interesting to 
note that for some of the specific seizure types 
described, immunosuppressive drugs (e.g., adreno- 
corticotropic hormone and/or corticosteroids) have 
been used in conjunction with anticonvulsants. 
Thus one could speculate that IVIG may be oper- 
ating through a putative immunomodulatory mech- 
anism. In seizures associated with a specific immu- 
nodeficiency (57, 58), IVIG may be exerting an 
effect against an etiologic agent. Again, these ques- 
tions will only be resolved with large-scale, well- 
controlled, prospective clinical trials. 
Multiple Sclerosis (MS) 
MS is a demyelinating disease of unknown etiol- 
ogy; however, considerable evidence exists for the 
role of immune mechanisms in its pathogenesis. A 
popular model includes a proposed initial viral 
infection followed by a secondary autoimmune pro- 
cess, principally directed at the perineural myelin 
sheaths. In extreme reactions the axis cylinders are 
also affected. Therapy has generally consisted of 
immunosuppressive drugs, principally ACTH and 
corticosteroids, plus symptomatic treatment. How- 
ever, several investigators, primarily in Europe, 
have also employed IVIG. These trials, like numer- 
ous others described herein, have been unblinded 
and nonrandomized with minimal controls. In an 
early attempt at using IgG to treat MS, Schuller and 
Govaerts (59) initially used intramuscular gamma- 
globulin, 5 g, given three times per week. This was 
subsequently changed to IVIG, 5 g, given once 
weekly. Their cohorts consisted of 31 MS patients 
with a mean duration of therapy of 4 years. The 
clinical course of these patients was compared to 
that of a control group of 164 patients receiving 
conventional therapy. Three response profiles were 
observed: (i) improvement (11 patients), (ii) no 
changes (9 patients), and (iii) deterioration (11 pa- 
tients). When compared to the course of the con- 
trols, the degree of improvement noted in the first 
group was statistically significant by several tests. 
In another trial Rothfelder et al. (60) treated 20 
MS patients with 5 g of IVIG administered every 2 
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months. Some clinical improvement, primarily in 
extremity symptoms, was noted, as well as a de- 
crease in the frequency of exacerbations. These 
authors concluded that more extensive and better- 
controlled additional trials are warranted. 
A summary of the experience of using gamma- 
globulin to treat MS has recently been published 
(6t). While it was recognized that it is still too early 
to judge the efficacy of gamma-globulin in the 
treatment of MS, it was also noted that some 
patients with severe, progressive exacerbations 
seemed to experience rapid neurological improve- 
ment with gamma-globulin treatment. 
Inflammatory Polyneuropathy 
Chronic ployneuropathies can occur in conjunc- 
tion with other disorders such as infections, malig- 
nancies, and collagen-vascular diseases or they may 
be idiopathic in origin. While their underlying 
pathologic mechanisms may be obscure, the fre- 
quent occurrence of mononuclear infiltrates of the 
affected nerves suggests the possibility of associ- 
ated immunopathology. Accordingly Vermeulen 
and colleagues have treated 17 patients with chronic 
inflammatory polyneuropathy with fresh-frozen 
plasma or high-dose IVIG (62). Improvement was 
observed in 13 of these patients. The rationale for 
this therapy was based on the effects of 1VIG for 
ITP. Of particular significance was the observation 
that improvement was seen after plasma or IVIG, in 
spite of the fact that no spontaneous remissions had 
been noted for 2 months prior. When plasma or 
IVIG was discontinued, the patients deteriorated 
clinically; however, upon reinstituting treatment 
they experienced significant improvement. Al- 
though the treatment effect was short-lived, im- 
provement could be reestablished with plasma or 
IVIG infusions, without any indication of becoming 
refractory to chronic therapy. The authors further 
suggest trials of IVIG for acute polyneuropathies. 
Systemic Lupus Erythematosus (SLE) 
Only a limited experience with IVIG treatment of 
SLE has been reported to date. Gaedicke et at. 
described the widely disparate responses of two 
adolescent girls with SLE to treatment with high- 
dose IVIG (63). While one patient achieved a long- 
lasting remission of a serious, acute exacerbation, 
no effect was seen with the other patient. It was 
implied that IVIG may be effective for ameliorating 
severe acute exacerbations of SLE but may not be 
of use in chronic disease, which may explain the 
different responses observed. 
Additional reports have also indicated marginal 
effects of IV1G on SLE. When six patients with 
SLE were treated with high-dose IVIG, the only 
clinical response was a brief improvement in their 
thrombocytopenia (64). Other symptoms generally 
remained unchanged; however, proteinuria in- 
creased secondary to IgG appearing in the urine. 
Circulating immune complexes, which were ele- 
vated prior to therapy, showed significant posttreat- 
ment reductions. Two infants born to mothers with 
active SLE who showed significantly decreased 
platelets and polymorphonuclear neutrophils soon 
after birth were treated with IVIG (65). Rapid 
amelioration of the children's cytopenias was ob- 
served. Recently two independent groups described 
the use of IVIG for several different patients with 
various collagen vascular disorders including SLE, 
juvenile rheumatoid arthritis, polymyositis, and 
Sjogren's syndrome (66, 67). While improvement 
and steroid sparing activity was noted, some of the 
effects were transient. These observations suggest 
that criteria for patient selection and optimal dosage 
remain to be determined. 
Although several unpublished reports on the use 
of IVIG in the treatment of SLE, including lupus 
glomerulonephritis, have also been presented at 
various meetings, it is still premature to determine 
the role of this therapy for SLE. More extensive, 
well-controlled trials may soon resolve this issue. 
Rheumatoid Arthrit& 
Like SLE, a paucity of published studies begs the 
question of whether IVIG may be useful in the 
treatment of rheumatoid arthritis (RA). In a very 
early report, Sany and co-workers describe the 
treatment of l0 hospitalized patients with severe 
RA using intravenous administration of a gamma- 
globulin preparation derived from human placentas 
(68). Significant but transient clinical improvement 
was noted in seven patients. A concomitant in- 
crease in both lymphocyte mitogen responses and 
percentages of "act ive" (E-rosette) T cells was also 
observed. In a much larger series of 31 patients with 
RA, approximately 60% of the study population 
experienced significant clinical improvement after 
the intravenous administration of a similar placenta- 
derived gamma-globulin preparation (69). While 
variable improvements were noted with regard to 
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the sedimentation rate and levels of rheumatoid 
factor, ANA, and levels of circulating immune 
complexes, all patients showed increased active E 
rosette-forming cells and a short-lived decline in Fc 
receptor-bearing lymphocytes. It was implied that 
in both of these studies the placental source of the 
gamma-globulins may have endowed them with 
unique immunosuppressive properties (e.g., anti- 
HLA-DR activity). 
Kawasaki Syndrome 
Kawasaki disease (KD) or mucocutaneous lymph 
node syndrome consists of a constellation of signs 
and symptoms including (i) fever of unknown etiol- 
ogy lasting 5 days or more, (ii) bilateral injection of 
the ocular conjunctivae, (iii) perioral and oropha- 
ryngeal changes and inflammation, (iv) cervical 
adenitis, (v) involvement of extremities (palmar and 
plantar erythema, edema, and desquamation), and 
(vi) polymorphous truncal examthem (70). Al- 
though the basic pathogenic mechanisms underly- 
ing KD are presently poorly understood, neverthe- 
less, much evidence indicates that it may be an 
immunologically medicated disorder. Because of a 
presumed immunologic basis for KD, especially the 
presence of potentially pathologic soluble circulat- 
ing immune complexes, Furosho et al. undertook a 
multicenter, controlled trial of high-dose IVIG plus 
aspirin versus aspirin alone for the treatment of 
patients with KD (71). They reported that the IVIG 
regimen appeared to reduce the frequency of coro- 
nary artery abnormalities. These results were con- 
firmed in a subsequent controlled, American study 
(72). Hence the Committee on Infectious Diseases 
of the American Academy of Pediatrics has issued 
guidelines for the use of IVIG in children with KD 
(73). Recently, however, Mason et at. examined the 
effects of IVIG on circulating immune complexes 
(CICs) in patients with CD (74). Although increased 
levels of CICs were noted, IVIG therapy did not 
appear to decrease their prevalence. Hence the 
authors concluded that CICs are not likely to be the 
primary immunopathologic mechanism of KD. 
KD has been the subject of much clinical and 
basic research (75). Several investigators have fo- 
cused on a possible infectious etiology. Until these 
issues are resolved, high-dose IVIG therapy insti- 
tuted within 10 days after the onset of disease 
appears to reduce significantly the morbidity and 
mortality of associated cardiovascular complica- 
tions (76). 
Insulin-Dependent Diabetes Mellitus (1DDM) 
Considerable evidence exists to support an au- 
toimmune basis for IDDM or type I diabetes. In 
addition to the demonstration of islet cell-specific 
autoantibodies in serum during the onset of disease, 
postmortem examinations have also revealed coex- 
isting infiltration of the islets of Langerhans with T 
lymphocytes (i.e., "insulitis"). Recent studies have 
indicated that immunomodulatory agents such as 
cyclosporin A may retard progression of disease 
(77). In an uncontrolled clinical trial, six children 
with recently diagnosed IDDM were treated with 
high-dose IVIG for up to 6 months (78). Four 
children demonstrated a prolonged partial remis- 
sion. 
A larger, controlled trial of high-dose IVIG using 
20 newly diagnosed patients, also treated for up to 6 
months, further indicated that this form of therapy 
may be an adjunct to conventional treatment (79). 
Most significant was a difference in insulin require- 
ments between the treated and the untreated pa- 
tients, with the latter necessitating a larger mainte- 
nance dose than the former. Accompanying the 
decreased insulin requirement was a concomitant 
increase in serum C-peptide levels. No other immu- 
nologic parameters showed any differences be- 
tween the treated and untreated groups. 
These intriguing observations warrant further fol- 
low-up, as cyclosporin A is associated with serious 
side effects; perhaps combination therapy with 
high-dose IVIG may permit a dosage reduction of 
the former while retaining efficacy. 
Bullous Pemphigoid 
Bullous pemphigoid is a severe, autoimmune blis- 
tering disease secondary to autoantibodies which 
recognize antigens of the basement membrane. 
Conventional therapy for pemphigoid usually con- 
sists of steroids, immunosuppressive drugs, and/or 
plasmapheresis. Godard and colleagues described 
the treatment of 11 patients with buUous pemphi- 
goid with IVIG (80). Rapid but transient responses 
were noted in eight patients, only one of whom had 
a prolonged remission. The authors speculate that 
combination therapy of IVIG with steroids may 
have a steroid-sparing effect. 
PROPOSED MECHANISMS OF ACTION 
While the rationale of IVIG replacement therapy 
for antibody deficiency states is obvious, its role as 
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an immunomodulating agent is less well under- 
stood. Several hypotheses have been evoked to 
explain the mechanisms by which IVIG may be 
effective in treating the numerous autoimmune dis- 
orders previously described. It is beyond the scope 
of this report to present these theories in detail. 
Rather, a brief summary of several currently popu- 
lar propositions is described. 
The efficacy of intact, native IgG as an immuno- 
modulator is consistent with a model which sug- 
gests that unbound IgG, particularly when in ex- 
cess, may compete with IgG complexed to antigens 
for Fc receptors on the surface of phagocytic cells 
in circulation and within the reticuloendothelial 
system. These cells are very effective in eliminating 
immune complexes (e.g., antibodies bound to cel- 
lular components such as RBCs, PMNs, platelets, 
hematopoietic stem cells, etc.) Thus blockage of Fc 
receptors with unbound IgG may inhibit destruction 
of autoantibody-bearing cells. 
Jerne's network theory of immunoregulation is 
conceptually dependent upon the existence of nat- 
urally occurring antiidiotypic antibodies in circula- 
tion (81). Antiidiotypic antibodies specific for the 
idiotypes of various autoantibodies may be consti- 
tutively present in the serum of healthy individuals 
as a normal immunoregulatory mechanism. These 
antiidiotypic antibodies may selectively target 
plasma cells or other members of the B-lymphocyte 
lineage bearing membrane-bound autoantibodies 
for complement-dependent and/or cell-mediated cy- 
totoxicity, thereby eliminating potential clones of 
autoantibody-producing cells. 
The role of infectious agents has also considered 
in the pathogenesis of some autoimmune reactions. 
Binding of antigens from etiologic agents to host 
cells may initiate an autoimmune response to the 
complex of neoantigen plus host-cell ("self") anti- 
gens. The elimination of the infectious agent with 
IV1G could thus break such a vicious cycle. 
Support for one or several of the above proposals 
may be found in the literature. Only additional 
studies, both in vivo and in vitro, will define the 
mechanisms underlying the well-demonstrated im- 
munomodulatory activities of IVIG. 
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